TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κ B p65: Single Nucleotide Polymorphism and Estrogen Dependence^[S]

Ming-Fen Ho, Edroaldo Lummertz da Rocha, Cheng Zhang, James N. Ingle, Paul E. Goss, Lois E. Shepherd, Michiaki Kubo, Liewei Wang, Hu Li, and Richard M. Weinshilboum

Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (M.H., E.L.d.R., C.Z., L.W., H.L., R.M.W.), and Division of Medical Oncology, Department of Oncology (J.N.I.), Mayo Clinic, Rochester, Minnesota; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts (P.E.G.); Canadian Cancer Trials Group, Kingston, Ontario, Canada (L.E.S.); and RIKEN Center for Integrative Medical Science, Yokohama, Japan (M.K.)

Received January 10, 2018; accepted March 19, 2018

ABSTRACT

T-cell leukemia 1A (*TCL1A*) single-nucleotide polymorphisms (SNPs) have been associated with aromatase inhibitor-induced musculoskeletal adverse events. We previously demonstrated that *TCL1A* is inducible by estradiol (E_2) and plays a critical role in the regulation of cytokines, chemokines, and Toll-like receptors in a *TCL1A* SNP genotype and estrogen-dependent fashion. Furthermore, *TCL1A* SNP-dependent expression phenotypes can be “reversed” by exposure to selective estrogen receptor modulators such as 4-hydroxytamoxifen (4OH-TAM). The present study was designed to comprehensively characterize the role of *TCL1A* in transcriptional regulation across the genome by performing RNA sequencing (RNA-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) assays with lymphoblastoid

cell lines. RNA-seq identified 357 genes that were regulated in a *TCL1A* SNP- and E_2 -dependent fashion with expression patterns that were 4OH-TAM reversible. ChIP-seq for the same cells identified 57 *TCL1A* binding sites that could be regulated by E_2 in a SNP-dependent fashion. Even more striking, nuclear factor- κ B (NF- κ B) p65 bound to those same DNA regions. In summary, *TCL1A* is a novel transcription factor with expression that is regulated in a SNP- and E_2 -dependent fashion—a pattern of expression that can be reversed by 4OH-TAM. Integrated RNA-seq and ChIP-seq results suggest that *TCL1A* also acts as a transcriptional coregulator with NF- κ B p65, an important immune system transcription factor.

Introduction

We previously performed a genome-wide association study (GWAS) that identified three single-nucleotide polymorphisms (SNPs) located 3' of the T-cell leukemia 1A (*TCL1A*) gene that were associated with musculoskeletal adverse events induced by aromatase inhibitors (AIs) (Ingle et al., 2010). The top hit SNP (rs11849538) from that GWAS was in tight linkage disequilibrium with two other SNPs, rs7160302 and rs7359033 ($R^2 = 0.92$ and 0.98, respectively) (Ho et al., 2016a). Subsequently, we performed functional genomic studies using a human variation panel of lymphoblastoid cell lines (LCLs), and we found that

TCL1A expression was induced by estradiol (E_2), but only in cell lines homozygous for variant genotypes for the *TCL1A* SNPs (Ho et al., 2016a). These three SNPs appeared to act in concert to influence estrogen-dependent *TCL1A* induction (Ho et al., 2016a). However, this expression pattern could be “reversed” after estrogen receptor α blockade with the active tamoxifen metabolite 4-hydroxytamoxifen (4OH-TAM).

We have also reported that mechanisms underlying this drug-induced reversal of *TCL1A* expression are due, at least in part, to altered estrogen receptor binding to estrogen response elements, two of which are at a distance from the SNPs (Ho et al., 2016a). Even more striking, a series of downstream immune mediator genes, including those encoding cytokines (Liu et al., 2012), chemokines (Ho et al., 2016a), and Toll-like receptors (TLRs) (Ho et al., 2017), responded in parallel with *TCL1A* SNP- and estrogen-dependent transcription. These observations have potential implications for the treatment of inflammatory diseases such as rheumatoid arthritis because their drug treatment targets these immune mediators. If the

This work was supported in part by the National Institutes of Health National Institute of General Medical Sciences [U19 GM61388 and R01 GM28157] and National Cancer Institute [P50 CA11620, R01 CA196648, and R01 CA138461]; the Avon Breast Cancer Crusade, the Breast Cancer Research Foundation, and the Mayo Clinic Center for Individualized Medicine. R.M.W. and L.W. are cofounders and stockholders in OneOme.

<https://doi.org/10.1124/jpet.118.247718>.

[S] This article has supplemental material available at jpet.aspetjournals.org.

ABBREVIATIONS: AI, aromatase inhibitor; bp, base pair; ChIP, chromatin immunoprecipitation; ChIP-seq, chromatin immunoprecipitation sequencing; DAPI, 2-(4-amidinophenyl)-1H-indole-6-carboxamide; E_2 , estradiol; EMSA, electrophoretic mobility shift assay; FBS, fetal bovine serum; GWAS, genome-wide association study; IP, immunoprecipitation; kb, kilobase; LCL, lymphoblastoid cell line; NF- κ B, nuclear factor κ B; 4OH-TAM, 4-hydroxytamoxifen; RA, rheumatoid arthritis; PCR, polymerase chain reaction; RNA-seq, RNA sequencing; siRNA, small interfering RNA; SNP, single-nucleotide polymorphism; *TCL1A*, T-cell leukemia 1A; TLR, Toll-like receptor.

TCL1A SNP genotypes were known, these observations raise the possibility that immune mediator gene expression could be manipulated by the use of drugs such as 4OH-TAM.

The molecular mechanisms underlying the effect of the *TCL1A* SNPs that result in changes in *TCL1A* expression in an estrogen- and 4OH-TAM-dependent fashion are not clear. The molecular mechanisms by which *TCL1A* expression might be associated with AI-induced musculoskeletal adverse events also remain unclear. Our study was designed to explore those molecular mechanisms. Specifically, we set out to determine whether *TCL1A* might function as a transcription factor that acts broadly—genome-wide—in a SNP- and estrogen-dependent fashion, and to study underlying mechanisms responsible for this genomic phenomenon using a human variation panel LCL model system.

We should emphasize that this LCL panel represents a genomic data-rich cell line model system that has repeatedly demonstrated its utility in the generation and testing of pharmacogenomic hypotheses (Ingle et al., 2010, 2013, 2016; Liu et al., 2012; Ho et al., 2016a, 2017). Specifically, it allowed us to select LCLs for study with any common genotype or combinations of genotypes, as demonstrated by the experiments described subsequently.

Materials and Methods

Human Variation Panel Lymphoblastoid Cell Lines

The human variation panel LCL model system consists of 300 LCLs from healthy subjects of three ethnicities (100 European American, 100 African American, and 100 Han Chinese American). This LCL cell line model system was used to perform many of the experiments described in this report. This cell line model system provides genome-wide mRNA expression as determined by Affymetrix (Santa Clara, CA) U133 2.0 Plus GeneChip expression arrays. SNP data were generated by the Illumina 550K and 510S SNP BeadChip SNP array (Illumina, San Diego, CA), and genotyping data were then used to impute approximately 7 million SNPs per cell line (Liu et al., 2012).

RNA Sequencing and Data Analysis

RNA was isolated from LCLs with known *TCL1A* SNP genotypes (two LCLs with homozygous wild-type and three LCLs with homozygous variant genotypes for the *TCL1A* SNPs). RNA sequencing (RNA-seq) experiments were conducted by the Mayo Clinic Center for Individualized Medicine Medical Genomics Facility. RNA-seq libraries were prepared with the Ovation RNA-seq system v2 kit (NuGEN, San Carlos, CA) according to the manufacturer's instructions, and they were sequenced using an Illumina HiSeq 2000 with six samples in each lane using 100-base pair (bp) paired-end index reads. Fastq files containing paired RNA-seq reads were aligned with Tophat 2.0.12 (Kim et al., 2013) against the University of California–Santa Cruz (UCSC) human reference genome (hg19) using Bowtie 2.2.3 with default settings (Langmead and Salzberg, 2012). Gene level counts from uniquely mapped, nondiscordant read pairs were obtained using the subRead featureCounts program (v1.4.6) (Liao et al., 2013) and gene models from the UCSC hg19 Illumina iGenomes annotation package. Size factors were computed using the estimateSizeFactors function of DESeq2, and reference genes (GAPDH, ACTB) as the controlGenes parameter for estimateSizeFactors by the DESeq2 package (Love et al., 2014). Differential expression analysis was also performed using the DESeq2 package with default parameters.

Identification of Genes with *TCL1A* Expression Patterns

To identify genes with expression patterns similar to that of *TCL1A* after drug or hormone treatment, we mined our transcriptome

data to identify genes that were up-regulated with $\log_2\text{FC} > 1$ only in LCLs homozygous for wild-type sequences for the *TCL1A* SNPs in response to E_2 treatment, and LCLs homozygous for variant genotypes for the *TCL1A* SNPs with nonsignificant changes or down-regulated ($\log_2\text{FC} < 0.5$) expression in response to E_2 treatment. We also searched for genes that had “reversed” gene expression patterns in response to E_2 +4OH-TAM treatment. Specifically, these were genes that were up-regulated with $\log_2\text{FC} > 1$ only in LCLs with homozygous variant sequences for the *TCL1A* SNPs in response to E_2 +4OH-TAM treatment, and LCLs with homozygous wild-type genotypes for the *TCL1A* SNPs that displayed nonsignificant changes or down-regulation ($\log_2\text{FC} < 0.5$) in response to E_2 +4OH-TAM treatment. Gene ontology terms for each data set were generated using Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (<https://david.ncicrf.gov/>) (Huang et al., 2009).

Chromatin Immunoprecipitation Sequencing and Data Analysis

The chromatin immunoprecipitation sequencing (ChIP-seq) experiments were performed in duplicate using two LCLs with known *TCL1A* genotypes. Specifically, we selected one LCL from each genotype group from the five LCLs we used to perform RNA-seq. The ChIP-seq libraries were prepared using the Ovation ultralow DR Multiplex kit (NuGEN), and were subsequently sequenced to 51-bp paired ends using Illumina HiSeq 2000 at the Mayo Clinic Center for Individualized Medicine Medical Genomics Facility. The Fastq files were aligned against the UCSC human reference genome (hg19) with Bowtie 1.1.0 using the following Bowtie parameters: `-sam -chunkmbs 512 -p 4 -k 1 -m 1 -e 70 -l 51 -best`. We then used the HOMER function findPeaks with default parameters to identify significantly enriched peaks in the experimental samples (Heinz et al., 2010).

We used deepTools to visualize binding profiles for *TCL1A* around transcription start sites (-2 kb, $+2$ kb) (Ramírez et al., 2016). Briefly, sorted bam files were used as input for the deepTools bamCoverage function using the parameter `-normalizeTo1x 2451960000` for normalization and generating BigWig files. We then used the function computeMatrix with `binSize = 20` to compute scores for genome regions, and we used its output to plot a heat map of *TCL1A* binding profiles across vehicle- and drug-treatment conditions using the deepTools function plotHeatmap. To identify regions with distinct binding intensities, we clustered binding profiles into four clusters using k-means.

Next, we used the ChipSeeker package to annotate peaks identified by HOMER and study the distribution of read densities around annotated genomic regions. Motif analyses were performed using the HOMER function findMotifsGenome with the parameter `size 50 -mask` to identify transcription factor-binding motifs. The accession number for the p65 ChIP-seq data are GSE55105 (Zhao et al., 2014).

Overlap analysis for genome-wide *TCL1A* and p65 binding sites was performed using a window of ± 500 bp from the center of each peak of *TCL1A* binding, and the binding signals of *TCL1A* and p65 were plotted side by side for each window, as shown in Fig. 5B. Figure 5C sums the ChIP-seq signals for *TCL1A* and p65 bindings, respectively, using a window ± 1000 bp from the transcription start site from each of the 357 *TCL1A* target genes we studied. Correlations were then calculated between *TCL1A* and p65 binding for each treatment condition.

CRISPR/Cas9 Plasmids and Knockout *TCL1A* Gene. *TCL1A* Double Nickase Plasmid sc-402028-NIC (Santa Cruz Biotechnology, Dallas, TX) was transfected into LCLs using the program X-001 of Amaxa Nucleofector (Lonza, Köln, Germany), and re-covered for 24 hours in RPMI1640 medium (Cellgro, Manassas, VA) supplemented with 15% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA). Transfected cells were cultured in medium containing $0.2 \mu\text{g/ml}$ of puromycin for 10 days for selection. Cells were seeded on a 96-well culture plate using RPMI1640 medium

supplemented with 15% FBS for 12 weeks. *TCL1A* expression was quantified and normalized to the β -actin signal by Western blot analysis. Cells exhibiting <10% normalized *TCL1A* signal were considered to have *TCL1A* knocked out.

Drug Treatment

LCLs with known genotypes were cultured in RPMI 1640 medium (Cellgro) supplemented with 15% FBS (Atlanta Biologicals). Before estrogen treatment, the cells were cultured in RPMI media containing 5% (v/v) charcoal-stripped FBS for 24 hours, and were subsequently cultured in FBS-free RPMI medium for another 24 hours. The cells were then treated with 0.1 nM of E_2 for 24 hours. In some experiments, the cells were treated with 4OH-TAM (10^{-7} μ M).

Real-Time Polymerase Chain Reaction

Four cell lines with each *TCL1A* genotype were selected for functional validation. The polymerase chain reaction (PCR) mixture contained 100 ng of total RNA, 5 μ l of 2X VeriQuest SYBR green qPCR master mix (Affymetrix), 0.1 μ l of DNA polymerase, 1 μ l of gene-specific primer, and distilled water up to 10 μ l per reaction. GAPDH and ACTB were used as internal controls. Real-time PCR reactions were performed in duplicate using the ViiA 7 Real-Time PCR System (Applied Biosystems/Life Technologies, Carlsbad, CA). The $2^{-\Delta\Delta C_t}$ method was employed for statistical data analysis.

RNA Interference and Transfection

Pooled *TCL1A*, p65 siRNA, and negative control were purchased from Dharmacon (Chicago, IL). Small interfering RNA (siRNA) was transfected into the LCLs by electroporation using the nucleofector kit (Lonza). Briefly, the electroporation reaction contained 2.5×10^6 cells, 100 μ l of nucleofector solution, and 300 nM siRNA. After electroporation, the cells were transferred into 12-well plates containing pre-equilibrated RPMI medium for use in the experiments described in this report.

Chromatin Immunoprecipitation Assay and ChIP-re-ChIP Assay

ChIP assays were performed using LCLs with known *TCL1A* SNP genotypes ($n = 4$ for each genotype) using the EpiTect ChIP OneDay Kit (Qiagen, Valencia, CA). DNA-*TCL1A* complexes were immunoprecipitated using antibodies against *TCL1A*, RelA, or with normal mouse IgG (Cell Signaling Technology, Danvers, MA) as a control. ChIP-re-ChIP assays were performed using the Re-ChIP-IT Kit (Active Motif, Carlsbad, CA). Real-time PCR was used to quantify *TCL1A* binding or p65 binding. The primer sets for the ChIP assays are listed in Supplemental Table 4.

Coimmunoprecipitation of *TCL1A* and Nuclear Factor κ B

The LCLs (1×10^7) were resuspended in 650 μ l of immunoprecipitation (IP) lysis buffer containing 2.2 μ l of protease inhibitor cocktail (Qiagen) and were incubated on ice for 30 minutes. The cells were then centrifuged at 12,000g at 4°C for 15 minutes. The supernatants were collected. Protein A agarose (ThermoScientific, Madison, WI) was prepared and washed 3 times with IP lysis buffer. A precleaning step was performed to clean the background. Cell lysates containing protein A agarose beads were rotated at 4°C for an hour. After centrifugation, the supernatant was collected. At this point, input (50 μ l) was collected and stored at -80°C .

Anti-*TCL1A* (1:50) (Cell Signaling Technology) or anti-nuclear factor κ B (anti-NF- κ B) p65 (1:50) antibodies (Abcam, Cambridge, MA) were used to perform IP. IgG (Cell Signaling Technology) was used as the negative control. Specifically, IP samples containing protein A agarose beads were rotated at 4°C overnight. Immunoprecipitates were washed 3 times with ice-cold lysis buffer, and the proteins were eluted with 50 μ l of 1X Laemmli loading buffer. The

proteins were separated on 4%–12% SDS-PAGE gels and transferred onto polyvinylidene fluoride membranes. After blocking, membranes were incubated with primary antibodies against *TCL1A* or NF- κ B p65 at 4°C overnight. The washed membrane was then incubated with secondary antibody (1:15,000 dilution) for an hour at room temperature. The membrane was visualized using super signal ECL substrate (ThermoScientific).

Electrophoretic Mobility Shift Assay

Recombinant Human *TCL1A* Protein (NBP1-30239) was purchased from Novus Biologicals (Littleton, CO). Synthetic oligonucleotides (sense and antisense) were derived from *TCL1A* response element sequences. Double-stranded DNA probes were 3' end-labeled with biotin (IDT, Coralville, IA). A 100-fold excess of unlabeled oligonucleotide competitors was used for the competition experiments. The reaction mixture was then loaded onto a 5% Tris/Borate/EDTA native polyacrylamide gel and electrophoresis was run for 1 hour at 100 V in $0.5 \times$ Tris/Borate/EDTA buffer. The protein–DNA complexes were transferred to Biotinylated Nylon Membranes (ThermoScientific) and UV cross-linked. An electrophoretic mobility shift assay (EMSA) was performed using LightShift Chemiluminescent EMSA Kit (ThermoScientific).

Immunofluorescence Staining and Confocal Imaging Analysis

LCLs were grown on glass coverslips and treated with 0.1 nM E_2 for 24 hours. The cells were then fixed in 4% paraformaldehyde at room temperature for 10 minutes. The cells were washed in cold phosphate-buffered saline and permeabilized with 0.2% Triton X-100. After blocking for 1 hour with 3% bovine serum albumin, the cells were incubated with mouse anti-*TCL1A* antibody (Cell Signaling Technology) overnight at 4°C. The secondary antibody (red) was ab150119 Alexa Fluor 647 goat anti-mouse IgG (H+L) used at 1:1000 dilution for an hour. DAPI [2-(4-amidinophenyl)-1H-indole-6-carboxamide] was used to stain the cell nuclei (blue) at a concentration of 1.43 μ M. The slides were visualized using fluorescence microscopy (FV1200; Olympus, Tokyo, Japan).

Results

RNA-Seq Genome-wide Identification of *TCL1A* SNP- and Estrogen-Dependent Transcription Regulation.

As a first step, RNA-seq was performed using LCLs selected for either homozygous wild-type or homozygous variant genotypes for the *TCL1A* SNPs shown graphically in Fig. 1A. The cells were treated with vehicle, E_2 , or $E_2 + 4\text{OH-TAM}$. The drug concentrations used had been optimized as shown in Supplemental Fig. 1 (Liu et al., 2012; Ho et al., 2016a, 2017). We then randomly selected 39 genes for use in the validation of the RNA-seq data and found very high reproducibility based on the use of qPCR (Supplemental Fig. 2). For example, in the presence of E_2 , *TCL1A* expression was induced in LCLs that were homozygous variant but not in those with homozygous wild-type genotypes for the *TCL1A* SNPs (Fig. 1B).

As expected, this expression pattern could be reversed in the presence of 4OH-TAM. Specifically, *TCL1A* expression was significantly up-regulated in cells that were homozygous wild-type for the *TCL1A* SNPs but not in those with homozygous variant genotypes (Fig. 1B). Based on the RNA-seq data, 357 genes displayed this *TCL1A* SNP- and estrogen-dependent gene expression pattern—a pattern that could be reversed by 4OH-TAM (Fig. 1C), in parallel with the pattern of expression of *TCL1A* itself in response to treatment with either E_2 or $E_2 + 4\text{OH-TAM}$ (Fig. 1B).

Fig. 1. (A) Schematic diagram of three *TCL1A* SNPs: rs11849538, the “top hit” signal from the MA.27 musculoskeletal adverse event GWAS, rs7359033, and rs7160302. All three of these SNPs map near the 3'-terminus of *TCL1A* and are in tight linkage disequilibrium. Locations of estrogen response elements (EREs) are shown as boxes. (B) SNP- and estrogen-related variation of *TCL1A* mRNA expression in lymphoblastoid cell lines with known *TCL1A* SNP genotypes after exposure to E_2 with or without 4OH-TAM. Student's *t* test was performed to compare gene expression in LCLs with differing *TCL1A* SNP genotypes for each treatment condition, ****P* < 0.001. (C) Heat map showing expression profiles for 357 genes regulated by *TCL1A* SNPs in an estrogen-dependent fashion, all of which could be reversed by 4OH-TAM treatment, as determined by RNA-seq using LCLs with either homozygous wild-type (W/W) (*n* = 2) or homozygous variant (V/V) (*n* = 3) genotypes for the *TCL1A* SNPs.

Specifically, a total of 357 genes could be significantly induced by E_2 with log 2-fold change ≥ 1 (Supplemental Table 1), but only in LCLs homozygous for *TCL1A* SNP variant genotypes (Fig. 1C). However, the expression of those same 357 genes was significantly induced in the presence of 4OH-TAM together with E_2 in LCLs that were homozygous for wild-type genotypes for the *TCL1A* SNPs (Fig. 1C).

We also performed gene ontology analysis and found that these 357 genes clustered within pathways involved in transcriptional regulation and T-cell activation (Supplemental Table 2) by using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (<https://david.ncicrf.gov/>) (Huang et al., 2009). These results provided additional information with regard to the role of *TCL1A* in the transcriptional regulation of immune mediators (Liu et al., 2012; Ho et al., 2016a,b). In the next series of experiments, we set out to directly test by ChIP-seq the possibility that *TCL1A* was a novel transcription factor that acts in a SNP- and estrogen-dependent fashion.

ChIP-Seq Genome-wide Identification of *TCL1A* Binding Sites. We next examined *TCL1A*'s binding profile on a genome-wide scale by performing ChIP-seq using the same set of LCLs that had been used in the RNA-seq studies. We clustered ChIP-seq peak signals within ± 2 kb from the transcription start site into four clusters using K-means. We observed that genes in cluster 1 were more strongly bound by *TCL1A* than genes in clusters 2 and 3, with higher enrichments in variant genotypes after E_2 treatment (Fig. 2A).

Therefore, *TCL1A* was found to bind preferentially to promoter regions. In addition, *TCL1A* also bound significantly in introns (~30% of sites) and intergenic regions (~23%) (Fig. 2B).

We also performed ChIP-qPCR experiments for 25 randomly selected sites using independent samples to confirm the specificity of these observations (Supplemental Fig. 3). The most significantly associated gene ontology terms for these genes involved pathways related to transcription regulation and immune function (Supplemental Table 3). This result confirmed our previous findings with regard to the effect of *TCL1A* on the expression of cytokines, chemokines, and their receptors (Supplemental Fig. 1), all of which play an important role in the regulation of immune responses. Our ChIP-seq results showed that *TCL1A* is capable of binding to specific DNA sequences across the human genome, resulting in the regulation of the transcription of target genes.

***TCL1A* Response Elements.** To identify in an unbiased fashion sequence motifs at sites occupied by *TCL1A*, we examined DNA sequences (50 bp $\pm$ from the peak) using HOMER (<http://homer.salk.edu/homer/ngs/>) (Heinz et al., 2010) and MEME (Bailey et al., 2009). De novo motif search in each set of *TCL1A* binding sites from these samples revealed enrichment of the consensus sequence 5'-CCATA-TATGG-3', which we designated as a *TCL1A* consensus DNA binding motif (Fig. 2C). We then performed EMSA using biotin-labeled *TCL1A* binding motif sequences and recombinant *TCL1A* protein to confirm that *TCL1A* protein could recognize and bind to this DNA motif sequence (Fig. 3A). The next series of studies was designed to characterize *TCL1A* as a novel transcription factor, with effects that occur with and without 4OH-TAM exposure.

Estrogen Significantly Alters *TCL1A* Occupancy of Binding Sites in or near Target Genes in a SNP-Dependent Fashion. In the absence of E_2 , *TCL1A* is mainly expressed in the cytoplasm and, to a lesser degree, in the cell membrane as determined by immunofluorescence staining of LCLs (Fig. 3B). However, *TCL1A* migrates and accumulates in the nucleus in the presence of E_2 (Fig. 3B). This observation is important because it supports the ability of *TCL1A* to translocate into the nucleus where it can function as a transcription factor, with effects that can be altered by estrogens and by the SNPs located 3' of *TCL1A*. For example, ChIP-seq showed that *TCL1A* was capable of binding to sites in the *CCR6* and *IL17RA* genes, both of which can be regulated by *TCL1A* in a SNP- and estrogen-dependent fashion (Ho et al., 2016a) (Fig. 3C).

Even more striking, the binding density depended on *TCL1A* SNP genotype and E_2 treatment (Fig. 3C). Specifically, *TCL1A* binding density in peaks in both *CCR6* and *IL17RA* was significantly higher in cells with homozygous variant genotypes for the *TCL1A* SNPs as compared with results for cells with homozygous wild-type genotypes. These results parallel those found during the RNA-seq studies (Fig. 3D).

It should be emphasized that the SNPs were located 3' of the *TCL1A* gene but not in *CCR6* or *IL17RA*. These observations led us to test whether the SNP- and estrogen-dependent expression of *TCL1A* might be associated with the transcription of *TCL1A* target genes. Therefore, the next series of studies was designed to integrate the ChIP-seq and RNA-seq data and to explore the possible role of

Fig. 2. (A) Genome-wide TCL1A occupancy profiles. Regions (Tss $\pm$ 2 kb) were clustered based on their profiles for TCL1A ChIP enrichment over input for all four samples using k-means clustering. Clustering was used to identify regions with distinct binding intensities. The gradient blue-to-red color indicates high-to-low counts in the corresponding genome region. (B) Percentage distributions of TCL1A ChIP-seq peaks for all four samples. (C) Identification of TCL1A consensus binding sequence motifs using HOMER and MEME.

TCL1A in transcriptional regulation in a SNP- and estrogen-dependent manner.

Integrated ChIP-Seq and RNA-Seq Analyses Reveal Functional TCL1A Binding Sites Associated with Transcriptional Regulation in a SNP-and Estrogen-Dependent Fashion. To explore the consequences of SNP-dependent TCL1A binding in or near target genes in response to E₂ treatment, we merged RNA-seq and ChIP-seq data by overlapping the results for genes that displayed *TCL1A* SNP-dependent gene expression and SNP-dependent TCL1A binding in response to E₂ treatment. A total of 357 genes could be induced by E₂ in a *TCL1A* SNP-dependent fashion, and 57 of

those genes also displayed binding of TCL1A with significantly increased binding density in response to E₂ treatment but only in the cells with homozygous variant genotypes for the *TCL1A* SNP genotypes (Fig. 4A). We confirmed this observation by performing ChIP-qPCR with primers specifically designed to amplify genomic regions for TCL1A binding sites in these genes.

Specifically, for all 57 TCL1A binding regions, greater TCL1A binding was observed in the presence of E₂ in cells with homozygous variant genotypes for the *TCL1A* SNPs as compared with those with wild-type genotypes (Fig. 4B). Furthermore, in the presence of 4OH-TAM this TCL1A

Fig. 3. (A) EMSA results showing that one TCL1A DNA binding motif sequence, CCATATAGG, is sufficient for DNA-TCL1A protein interaction. (B) Immunofluorescence staining showing TCL1A nuclear translocation in response to E₂ (0.1 nM) treatment in LCLs. (C) Representative examples of TCL1A occupancy peaks depicted for the *CCR6* and *IL17RA* loci in LCLs with known *TCL1A* SNP genotypes in the absence of E₂ or in the presence of E₂ (0.1 nM). Red boxes indicate that TCL1A binding in both *CCR6* and *IL17RA* is significantly increased in response to E₂ treatment, but that only occurs in cells with homozygous variant genotypes for *TCL1A* SNPs. (D) Changes in TCL1A occupancy are highly correlated with changes in mRNA expression levels for *CCR6* and *IL17RA*. Student's *t* test was performed to compare gene expression in LCLs with differing *TCL1A* SNPs (homozygous wild-type versus homozygous variant) for each treatment condition, ****P* < 0.001.

binding pattern was reversed (Fig. 4C). These results were compatible with the gene expression patterns for all 57 of these genes in response to E₂ treatment (Fig. 4D), all of which also displayed a reversal of expression in the presence

of 4OH-TAM (Fig. 4E) using the same cell lines from which the data shown in Fig. 4, B and C, were obtained. It should be pointed out once again that the SNPs were located 3' of *TCL1A* and not in the 57 genes themselves. In summary, this series of

Fig. 4. (A) Venn diagram showing 357 gene that displayed *TCL1A* SNP- and estrogen-dependent gene expression patterns as determined by RNA-seq, and 57 of those 357 genes that displayed *TCL1A* SNP- and estrogen-dependent *TCL1A* occupancy. (B and C) *TCL1A* ChIP assays were performed to confirm results obtained from *TCL1A* ChIP-seq for all 57 genes, all of which showed greater *TCL1A* binding in the presence of E_2 , but only in cells homozygous variant for the *TCL1A* SNP genotypes. In contrast, in the presence of 4OH-TAM, this binding pattern was reversed for all 57 genes ($n = 4$ for each genotype group). (D and E) Changes in *TCL1A* binding were correlated with changes in mRNA expression for all 57 genes using the same cell lines from which the data shown in B and C were obtained. Specifically, in the presence of E_2 , all those genes showed significant induction only for the variant genotype. However, the expression pattern could be reversed by 4OH-TAM, thus confirming that changes in *TCL1A* occupancy were highly correlated with transcription.

experiments demonstrated clearly that *TCL1A* served as a transcription factor for these target genes in a SNP- and estrogen-dependent fashion.

***TCL1A* and NF- κ B p65 Co-occupy Binding Sites on *TCL1A*-Responsive Target Genes.** We also interrogated the sequences of the *TCL1A* binding sites (peak ± 50 bp) for overrepresentation of known DNA binding motifs using HOMER. An NF- κ B p65 binding motif was highly enriched in these genomic regions (with P values = $1E-12$ and $1E-38$ for cells with homozygous wild-type or homozygous variant genotypes for the *TCL1A* SNPs, respectively). These observations led us to determine whether *TCL1A* might physically interact with NF- κ B p65 and, as a result, might serve as a transcriptional coregulator with NF- κ B p65.

Possible protein-protein interaction between *TCL1A* and NF- κ B p65 was determined by coimmunoprecipitation (co-IP) using LCLs with endogenous expression of both *TCL1A* and NF- κ B p65 (Fig. 5A). Reverse IP verified the physical association between NF- κ B p65 and *TCL1A* (Fig. 5A). We next tested whether both *TCL1A* and NF- κ B p65 might target the same genes and/or regulatory elements. To do that, we compared our *TCL1A* ChIP-seq dataset and publicly available p65 ChIP-seq dataset generated for LCLs (Zhao et al., 2014). There was a high degree of overlap between the locations of peaks for the two transcription factors (Fig. 5B).

It should be pointed out that the heat map for p65 binding sites shown in Fig. 5B used a window ± 500 bp centered on *TCL1A* peaks genome-wide, which indicated that p65 bound to genome regions similar to those to which *TCL1A* bound. This overlap suggested a possible functional relationship between *TCL1A* and p65 in the regulation of gene expression, including genes involved in immune response. This overlap was particularly striking for the 357 genes shown in Fig. 1C, genes that could be regulated by *TCL1A* in a SNP- and estrogen-dependent manner (Fig. 5C). Therefore, we next attempted to determine whether *TCL1A* and the NF- κ B p65 subunit might interact within the same transcriptional complex by performing ChIP-re-ChIP assay.

Those experiments showed that *TCL1A* and NF- κ B p65 co-occupied the same sites on *TCL1A* target genes, as shown in Fig. 6, A and B, based on the results of ChIP-re-ChIP assays performed using antibody against *TCL1A*, followed by antibody against NF- κ B p65. Even more striking, the binding pattern for NF- κ B p65 displayed a *TCL1A* SNP- and estrogen-dependent pattern. Specifically, a significant increase in NF- κ B p65 binding was observed in cells with homozygous variant genotypes for the *TCL1A* SNPs in response to E_2 treatment (Fig. 6A). However, this binding pattern was reversed when the cells were exposed to 4OH-TAM (Fig. 6B), in parallel with the binding pattern for *TCL1A* that we had observed (Fig. 4, B and C). It should be emphasized once again that the SNPs being studied were located 3' of *TCL1A* not in the NF- κ B p65 gene or in the genes listed in Fig. 6, A and B.

TCL1A and p65 expression displayed a positive correlation in LCLs (Fig. 7A). Specifically, *TCL1A* knockout in LCLs using CRISPR-Cas9 resulted in the down-regulation of p65. NF- κ B p65 knockout resulted in cell death, so we used siRNA transient knockdown of this gene in our experiments. Similarly, knockdown of p65 in LCLs using siRNA caused down-regulation of *TCL1A* (Fig. 7A). Furthermore, *TCL1A* SNP- and estrogen-dependent binding to DNA often appeared to involve both *TCL1A* and NF- κ B p65. For example, the SNP-dependent binding pattern for *TCL1A* target genes was lost after the knockdown of p65 in LCLs with known *TCL1A* SNP genotypes (Fig. 7B). In parallel, the SNP- and estrogen-dependent p65 binding for *TCL1A* target genes was also abolished after *TCL1A* was knocked out (Fig. 7C). Furthermore, the *TCL1A* SNP- and estrogen-dependent gene expression pattern was also lost after p65 was knocked down (Fig. 7D) or *TCL1A* was knocked out (Fig. 7E).

Taken together, these data suggest that a *TCL1A* and NF- κ B p65 protein complex might contribute to *TCL1A* SNP- and estrogen-dependent transcription regulation, at least for some genes. We also observed that *TCL1A* SNP- and estrogen-dependent p65 binding was lost after *TCL1A*

A Co-Immunoprecipitation **B ChIP-seq** **C TCL1A and p65 ChIP-seq (357genes)**

Fig. 5. (A) Coimmunoprecipitation was used to determine whether TCL1A protein could interact with p65 in LCLs. Whole cell lysates from 1×10^7 LCLs were immunoprecipitated with (left panel) anti-TCL1A (1:50) antibodies or anti-IgG antibodies and protein samples were immunoblotted and probed with antibodies against TCL1A. Reversed IP was performed to confirm that p65 and TCL1A interacted (right panel). (B) Heat-map plots showing the association between TCL1A binding and p65 binding in LCLs (Zhao et al., 2014). The signals for TCL1A ChIP-seq peaks and p65 ChIP-seq peaks are shown as heat-maps using red (the strongest signal) and white (the weakest signal) color schemes. Each row shows ± 500 bp centered on the TCL1A ChIP-seq peak summits. (C) TCL1A occupancy versus p65 occupancy in LCLs. Scatter plots depicting the Pearson correlations (r) between TCL1A ChIP tag density (y axis) and p65 ChIP tag density (x axis) for the 357 TCL1A target genes are shown in Fig. 1C.

knockout (data not shown). These data suggested that TCL1A and NF- κ B p65 either co-occupy the same sites or that their binding sites are located very close together on TCL1A target genes, resulting in the SNP- and estrogen-dependent variation in gene expression that we observed.

Finally, TCL1A also appeared to interact with all NF- κ B subunits except for p52 (Fig. 8). However, relB, c-rel, and p50 were not able to bind the TCL1A target genes in areas of TCL1A binding (Supplemental Fig. 4). Taken as a whole, these results supported the conclusion that NF- κ B p65 may

Fig. 6. (A and B) p65 ChIP-re-ChIP assays were performed to confirm the co-occupancy of *TCL1A* and p65 on 57 selected binding regions as shown in Fig. 4, B and C ($n = 4$ for each genotype group).

play an important role in *TCL1A* SNP- and estrogen-dependent transcriptional regulation.

Discussion

We have studied mechanisms responsible for *TCL1A* SNP- and estrogen-dependent regulation of gene expression using a cell-line model system. *TCL1A* is expressed in immune cells including activated T lymphocytes, B lymphocytes, and thymocytes (Kang et al., 2005). Not only is the LCL model system well suited for these experiments because of the dense genomic data that we have generated for these cells, but also the Genotype-Tissue Expression (GTEx) Project database (<https://www.gtexportal.org/home/>) reports that, of all human tissues and cells included in that database, the highest expression of *TCL1A* is observed in LCLs (see Supplemental Fig. 5).

In the present study, we have demonstrated clearly that *TCL1A* is a novel transcription factor that acts in a SNP- and estrogen-dependent fashion. The three SNPs involved are located 3' of the *TCL1A* gene (Fig. 1A) and have been associated with AI-induced musculoskeletal adverse events (Ingle et al., 2010). The present study also demonstrated that *TCL1A* appears to serve as a transcriptional coregulator with the NF- κ B p65 subunit. Therefore, the present study represents an important step in the process of providing functional and mechanistic explanations for the association of *TCL1A* SNPs with inflammation and the immune response.

SNPs that map to the coding regions of genes or within DNA transcription factor binding motifs are well documented to have functional effects on the regulation of gene expression (Barrett et al., 2012). However, our present series of studies began with a GWAS that identified SNPs located 3' of *TCL1A* on chromosome 14 that were associated with AI-induced musculoskeletal pain (Ingle et al., 2010). The minor allele frequency for these SNPs is approximately 19% in all major human populations (European, African, and Asian Americans) based on 1000 Genomes Project data (The 1000 Genomes Project Consortium, 2015). We subsequently performed a series of functional genomic studies, which showed that *TCL1A* expression was up-regulated by E_2 only in cells

Fig. 7. (A) Western blot analysis after *TCL1A* knockout or p65 knockdown in LCLs. (B) Knockdown of p65 resulted in the abolition of SNP- and estrogen-dependent *TCL1A* occupancy. (C) Knockdown of *TCL1A* abolished the *TCL1A* SNP- and estrogen-dependent p65 binding. (D and E) *TCL1A* SNP- and estrogen-dependent gene expression was lost after the knockdown of p65 or the knockout of *TCL1A*.

carrying variant sequences for these SNPs. This SNP-dependent induction depended on functional estrogen response elements located—in part—at a distance from the SNPs (Fig. 1A) (Ho et al., 2016a). Furthermore, *TCL1A* induction was associated with variation in the expression of a series of immune mediators including cytokines, chemokines, and TLRs (Liu et al., 2012; Ho et al., 2016a, 2017). Finally, this SNP-estrogen-dependent pattern of gene expression could be “reversed” by 4OH-TAM (Liu et al., 2012; Ho et al., 2016a, 2017).

The present study in which we have performed RNA-seq and ChIP-seq using LCLs with known *TCL1A* SNP genotypes has greatly extended these previous observations (Fig. 1C). It should be emphasized that the SNPs involved in all these studies are those 3' of *TCL1A*. These SNPs were **not** in or near genes that were regulated by *TCL1A*. It should also be emphasized that basal expression levels were not significantly different for these inflammatory mediators from our previous reports or, as shown in Fig. 1C, between the two different genotype patterns for the *TCL1A* SNPs (homozygous wild-type versus homozygous variant). These results serve to

Fig. 8. Coimmunoprecipitation was used to determine whether TCL1A protein could interact with NF- κ B subunits in LCLs.

highlight the fact that genetically polymorphic variation in the expression of a transcription factor, in this case TCL1A, can have a profound influence on the transcriptional regulation of downstream genes, in this case in a SNP- and estrogen-dependent fashion (Fig. 1C).

The present study also identified a consensus sequence motif for a “TCL1A response element” that appeared to be a 10-bp palindromic inverted sequence (Fig. 2C). This TCL1A response element consensus sequence could be found near the center of a majority of the strong TCL1A bindings peaks that we observed. However, these regions might not be the only determinant of TCL1A binding to DNA. We also observed that high TCL1A occupancy at many of its binding sites was associated with the occurrence of NF- κ B p65 binding (Fig. 5B).

NF- κ B plays a pivotal role in inflammation (Makarov, 2001; Lawrence, 2009). Inflammatory mediators include cytokines, chemokines, and TLRs, all of which are thought to be crucial for immune function, and they can also have a profound effect on inflammation as a result of NF- κ B activation (Tak and Firestein, 2001). As outlined earlier, TCL1A can modulate the expression of these immune mediators in a SNP- and estrogen-dependent manner (Liu et al., 2012; Ho et al., 2016a, 2017). As a result, our study has not only greatly expanded our previous observations but also offers a novel mechanism by which NF- κ B p65 might act as a coregulator and contribute to *TCL1A* SNP- and estrogen-dependent transcription regulation, all of which provides possible pharmacogenomic explanations for the association of *TCL1A* SNPs with musculoskeletal adverse events induced by AI therapy. Therefore, future studies will be needed to test the possibility that, by silencing the *TCL1A* gene, TCL1A could be a drug target for the management of musculoskeletal symptoms induced by AI therapy.

Furthermore, observations made in the series of TCL1A functional genomic studies also provide insight into the expression of immune mediators that could potentially be pharmacologically manipulated in a SNP-dependent fashion and might have potential implications for the treatment of rheumatologic disease. For example, rheumatoid arthritis (RA) displays a strong sex bias toward women and reveals

profound variation in incidence and severity during periods of change in estrogen levels. The highest risk for RA is observed during the menopausal years (Goemaere et al., 1990), and the incidence of RA and the risk of “flares” are increased during the postpartum period, a time of rapidly decreased plasma estrogen levels (Peschken et al., 2012). These observations display interesting parallels to the clinical impact of the pharmaceutical lowering of estrogen levels by drugs such as the AIs. *TCL1A* SNP-dependent transcriptional regulation of immune mediators also provides insight into pharmacogenomic aspects of the regulation of the expression of inflammatory mediators such as IL17A and IL17RA, both of which are deeply involved in RA pathophysiology and are therapeutic targets for RA. If these observations can ultimately be translated into the clinic, they might represent a novel mechanism by which drugs could be used to regulate the estrogen-dependent induction of inflammatory mediator expression.

The present study used a genomic data rich cell-line model system to uncover a relationship between TCL1A and p65 DNA binding and variation in the regulation of gene expression. Obviously, transcription factor binding is regulated in a cell type-specific manner. However, the present study represents a critical step in the process of providing a functional and mechanistic explanation for *TCL1A* SNP- and estrogen-dependent gene expression regulation. This mechanism might contribute broadly to individual variation in transcriptional regulation, in immune response, and in variation in drug response—the phenotype that resulted in the discovery of this potentially important process in transcriptional regulation.

In conclusion, in this study we have greatly extended previous observations with regard to *TCL1A* SNP- and estrogen-dependent gene expression genome-wide by performing RNA-seq and ChIP-seq using LCLs with known *TCL1A* SNP genotypes. We have demonstrated clearly that TCL1A is a novel transcription factor that acts in a SNP- and estrogen-dependent fashion. The integrated RNA-seq and ChIP-seq data reported here also suggest that TCL1A may be a coregulator of expression acting together with the NF- κ B p65 subunit, a transcription factor that plays a key role in inflammation. As a result, the present study has greatly extended our understanding of the role of TCL1A in transcriptional regulation and has highlighted a novel mechanism for *TCL1A* SNP- and estrogen regulation of transcription—as a coregulator with NF- κ B p65. Obviously, future studies will be required to pursue the role of TCL1A in individual variation in immunity and inflammation as well as its possible role in the pathophysiology of human disease.

Authorship Contributions

Participated in research design: Ho, Lummertz da Rocha, Zheng, Li, Ingle, Goss, Shepherd, Kubo, Wang, Weinshilboum.

Conducted experiments: Ho.

Performed data analysis: Ho, Lummertz da Rocha, Zheng, Li, Ingle, Wang, Weinshilboum.

Wrote or contributed to the writing of the manuscript: Ho, Lummertz da Rocha, Zhang, Li, Ingle, Goss, Shepherd, Kubo, Wang, Weinshilboum.

References

- Bailey TL, Boden M, Buske FA, Frith M, Grant CE, Clementi L, Ren J, Li WW, and Noble WS (2009) MEME SUITE: tools for motif discovery and searching. *Nucleic Acids Res* 37:W202–W208.
- Barrett LW, Fletcher S, and Wilton SD (2012) Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. *Cell Mol Life Sci* 69:3613–3634.

- Goemaere S, Ackerman C, Goethals K, De Keyser F, Van der Straeten C, Verbruggen G, Mielants H, and Veys EM (1990) Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. *J Rheumatol* **17**:1620–1622.
- Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, and Glass CK (2010) Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**:576–589.
- Ho M-F, Bongartz T, Liu M, Kalari KR, Goss PE, Shepherd LE, Goetz MP, Kubo M, Ingle JN, Wang L, et al. (2016a) Estrogen, SNP-dependent chemokine expression and selective estrogen receptor modulator regulation. *Mol Endocrinol* **30**:382–398.
- Ho M-F, Ingle J, Goss P, Mushiroda T, Kubo M, Shepherd L, Wang L, and Weinshilboum R (2016b) Aromatase inhibitor-induced musculoskeletal symptoms and TCL1A SNP-mediated, TLR-MyD88-dependent NF- κ B activation: molecular mechanisms involving a crucial adaptor protein MyD88 (Abstract). *Clin Pharmacol Ther* **99** (Suppl 1):S78–S79.
- Ho M-F, Ingle JN, Bongartz T, Kalari KR, Goss PE, Shepherd LE, Mushiroda T, Kubo M, Wang L, and Weinshilboum RM (2017) TCL1A SNPs and estrogen-mediated Toll-like receptor-MYD88-dependent NF- κ B activation: SNP and SERM-dependent modification of inflammation and immune response. *Mol Pharmacol* **92**:175–184.
- Huang W, Sherman BT, and Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc* **4**:44–57.
- Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, et al. (2013) Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. *Cancer Discov* **3**:812–825.
- Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman J-AW, Kubo M, Jenkins GD, Batzler A, Shepherd L, et al. (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. *J Clin Oncol* **28**:4674–4682.
- Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, et al. (2016) Genetic polymorphisms in the long non-coding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy. *Cancer Res* **76**:7012–7023.
- Kang S-M, Narducci MG, Lazzeri C, Mongiovi AM, Caprini E, Bresin A, Martelli F, Rothstein J, Croce CM, Cooper MD, et al. (2005) Impaired T- and B-cell development in Tc1-deficient mice. *Blood* **105**:1288–1294.
- Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, and Salzberg SL (2013) TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* **14**:R36.
- Langmead B and Salzberg SL (2012) Fast gapped-read alignment with Bowtie 2. *Nat Methods* **9**:357–359.
- Lawrence T (2009) The nuclear factor NF- κ B pathway in inflammation. *Cold Spring Harb Perspect Biol* **1**:a001651.
- Liao Y, Smyth GK, and Shi W (2013) The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res* **41**:e108.
- Liu M, Wang L, Bongartz T, Hawse JR, Markovic SN, Schaid DJ, Mushiroda T, Kubo M, Nakamura Y, Kamatani N, et al. (2012) Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. *Breast Cancer Res* **14**:R41.
- Love MI, Huber W, and Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**:550.
- Makarov SS (2001) NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. *Arthritis Res* **3**:200–206.
- Peschken CA, Robinson DB, Hitchon CA, Smolik I, Hart D, Bernstein CN, and El-Gabalawy HS (2012) Pregnancy and the risk of rheumatoid arthritis in a highly predisposed North American Native population. *J Rheumatol* **39**:2253–2260.
- Ramírez F, Ryan DP, Grüning B, Bhargava V, Kilpert F, Richter AS, Heyne S, Dündar F, and Manke T (2016) deepTools2: a next generation web server for deep-sequencing data analysis. *Nucleic Acids Res* **44** (W1):W160–W165.
- Tak PP and Firestein GS (2001) NF- κ B: a key role in inflammatory diseases. *J Clin Invest* **107**:7–11.
- The 1000 Genomes Project Consortium (2015) A global reference for human genetic variation. *Nature* **526**:68–74.
- Zhao B, Barrera LA, Ersing I, Willox B, Schmidt SC, Greenfield H, Zhou H, Mollo SB, Shi TT, Takasaki K, et al. (2014) The NF- κ B genomic landscape in lymphoblastoid B cells. *Cell Reports* **8**:1595–1606.

Address correspondence to: Dr. Richard M. Weinshilboum, Mayo Clinic, 200 First Street SW, Rochester, MN 55905. E-mail: weinshilboum.richard@mayo.edu